Researchers have found a promising new method for gene therapy. They successfully restarted inactive genes by bringing them ...

CRSP bets on Casgevy to drive growth, but its extremely high price tag and slow rollout test investor patience in a crowded ...

The clinical-stage biotech is developing gene-editing CRISPR technology. Editas has reported encouraging testing results in ...

Learn about sickle cell disease, a genetic blood disorder affecting millions in India, with potential treatments and ...

Although sickle cell disease (SCD) is not as widespread in the Philippines compared to other populations, it is still worth ...

Anaemia in pregnancy can impact your baby's health. Learn how early detection and treatment can protect both mother and child ...

A compelling session at the EHA Congress explored how space research is reshaping our understanding of hematologic processes.

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $482.4, with a high estimate of $567.00 and a low estimate of $420.00. This current average ...

Turning a $10,000 investment into $1 million represents a financial dream for many — a 100x return that would require an ...